Lonza has reported the integration of its new assets into its
nutrition activities and saw demand increase for its existing store
of healthy ingredients in 2006 - yet margins continued to slide.
Higher raw material and energy costs, matched against a weak US
currency, sent sales for Swiss fine chemicals producer down 3.7 per
cent with operating profit plunging by 16.5 per cent.
Swiss fine chemicals company Lonza said today that Martin Ebner's
BZ Group Holding plans to sell its 19.8 per cent stake in the
business in the coming weeks in a bid to raise cash for the
investor group.
Lonza, the Swiss-based pharmaceuticals company, has said that the
US Food and Drug Administration has allowed the sale of PepZin GI,
a recent dietary ingredient submission to the federal agency.
Swiss life science company Lonza has agreed to sell its fatty acid
and glycerine operation in Ohio, USA to oleochemical producers Twin
Rivers Technologies.
Switzerland's Lonza group has confirmed its commitment to the
construction of a major new production facility in the town of Visp
with the announcement of a SFr100 million (€68.4m) investment in a
biopharmaceuticals manufacturing...
Swiss-based life science chemical company Lonza has set up a cGMP
manufacturing capacity for large scale solid phase manufacture of
peptides at its Visp (CH) facility.
